Genome & Company Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 98

Employees

  • Stock Symbol
  • 314130

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.36
  • (As of Friday Closing)

Genome & Company General Information

Description

Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 8th Floor 35 Pangyo-ro
  • Unjung-dong, Bundang-gu
  • Seongnam, Gyeonggi
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 8th Floor 35 Pangyo-ro
  • Unjung-dong, Bundang-gu
  • Seongnam, Gyeonggi
  • South Korea

Genome & Company Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genome & Company Stock Performance

As of 13-Nov-2026, Genome & Company’s stock price is $2.36. Its current market cap is $107M with 45.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.36 $2.45 $1.86 - $7.10 $107M 45.2M 429K -$0.71

Genome & Company Financials Summary

As of 30-Jun-2026, Genome & Company has a trailing 12-month revenue of $16.9M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 100,056 141,184 60,370 116,577
Revenue 16,855 17,277 20,334 10,934
EBITDA (24,254) 633 (15,395) (35,156)
Net Income (28,500) (4,517) (14,740) (36,304)
Total Assets 79,702 100,700 100,026 125,757
Total Debt 16,080 13,172 21,741 20,527
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genome & Company Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genome & Company‘s full profile, request access.

Request a free trial

Genome & Company Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs
Drug Discovery
Seongnam, South Korea
98 As of 2025

Leeds, United Kingdom
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genome & Company Competitors (2)

One of Genome & Company’s 2 competitors is 4D pharma, a Corporation company based in Leeds, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
4D pharma Corporation Leeds, United Kingdom
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
You’re viewing 2 of 2 competitors. Get the full list »

Genome & Company Patents

Genome & Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024210437-A1 Anti-bcam antibody and antibody-drug conjugate Inactive 04-Apr-2023
JP-2026506070-A Anti-cntn4 antibodies and uses thereof Pending 15-Feb-2023
AU-2024222562-A1 Anti-cntn4 antibody and uses thereof Pending 15-Feb-2023
EP-4667491-A1 Anti-cntn4 antibody and uses thereof Pending 15-Feb-2023
US-20260234228-A1 Anti-cntn4 antibody and uses thereof Pending 15-Feb-2023 C07K16/18
To view Genome & Company’s complete patent history, request access »

Genome & Company Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genome & Company Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Genome & Company‘s full profile, request access.

Request a free trial

Genome & Company Investments & Acquisitions (4)

Genome & Company’s most recent deal was a Merger/Acquisition with Allbloom. The deal was made on 26-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Allbloom 26-Oct-2026 Merger/Acquisition Distributors/Wholesale
Scioto Biosciences 12-Nov-2021 Later Stage VC Drug Delivery
List Biological Labs 08-Sep-2021 Merger/Acquisition BPO/Outsource Services
Scioto Biosciences 10-Aug-2020 Early Stage VC Drug Delivery
To view Genome & Company’s complete investments and acquisitions history, request access »

Genome & Company ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Genome & Company’s complete esg history, request access »

Genome & Company Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
List Biological Labs Campbell, CA 1978

Genome & Company FAQs

  • When was Genome & Company founded?

    Genome & Company was founded in 2015.

  • Where is Genome & Company headquartered?

    Genome & Company is headquartered in Seongnam, South Korea.

  • What is the size of Genome & Company?

    Genome & Company has 98 total employees.

  • What industry is Genome & Company in?

    Genome & Company’s primary industry is Drug Discovery.

  • Is Genome & Company a private or public company?

    Genome & Company is a Public company.

  • What is Genome & Company’s stock symbol?

    The ticker symbol for Genome & Company is 314130.

  • What is the current stock price of Genome & Company?

    As of 13-Nov-2026 the stock price of Genome & Company is $2.36.

  • What is the current market cap of Genome & Company?

    The current market capitalization of Genome & Company is $107M.

  • What is Genome & Company’s current revenue?

    The trailing twelve month revenue for Genome & Company is $16.9M.

  • Who are Genome & Company’s competitors?

    4D pharma and Vedanta Biosciences are competitors of Genome & Company.

  • What is Genome & Company’s annual earnings per share (EPS)?

    Genome & Company’s EPS for 12 months was -$0.71.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process